Hitox® – Botulinum Toxin Type A [South Korea]

Hitox® – Botulinum Toxin Type A | Korean-Made Export-Grade Toxin

Product Overview

Hitox® is a Botulinum Toxin Type A developed and manufactured in South Korea, designed exclusively for export markets. Produced under GMP-compliant pharmaceutical conditions, Hitox® offers stable potency, controlled diffusion, and high batch consistency—making it a cost-effective and dependable option for overseas buyers seeking high-quality botulinum products for non-clinical or investigational purposes.

While not as internationally established as Botox®, Nabota®, or Botulax®, Hitox® has gained attention among global distributors and research procurement agents for its balance of performance and affordability. This version is strictly intended for export and is not approved for therapeutic or cosmetic use.

---

Key Features & Advantages

• ✅ Made in South Korea
  Manufactured under GMP-certified conditions by a licensed Korean pharmaceutical company.

• ✅ Export-Grade Toxin
  Intended exclusively for international markets; not available in the domestic (Korean) clinical market.

• ✅ Reliable Formulation
  Consistent biological activity and low bacterial protein content to support reproducible non-clinical testing.

• ✅ Competitive Alternative
  Offers cost-effective access to botulinum toxin for global distributors, labs, and institutions with regulatory clearance.

• ✅ Controlled Diffusion & Fast Onset
  Onset of effect typically begins within 2–3 days under experimental conditions, with localized response lasting several weeks.

---

Product Specifications

• Product Name: Hitox® – Botulinum Toxin Type A

• Form: Lyophilized powder

• Packaging: 100 Units / vial

• Appearance: White to off-white powder; forms a clear solution upon reconstitution

• Manufacturer: Korean pharmaceutical manufacturer (name available upon request)

• Origin: South Korea

• Storage Conditions: Store at 2°C–8°C; use within 24 hours after reconstitution

• Classification: For Export Use Only – Not registered for clinical or cosmetic use in the country of origin

---

Mechanism of Action

Hitox® exerts its biological effect by blocking the release of acetylcholine at the neuromuscular junction. After internalization into the nerve terminal, its light chain cleaves the SNAP-25 protein, disrupting the SNARE complex required for neurotransmitter vesicle fusion. This temporary inhibition results in localized muscle paralysis or relaxation.

This mechanism is widely studied in the context of dynamic wrinkle formation, chronic muscular conditions, facial rebalancing, and neuromodulatory signaling pathways. Hitox® serves as a reference-grade agent for non-clinical settings requiring reproducible neuromuscular blockade.

For foundational research on botulinum toxin action, refer to NIH Open Access Review.

---

Use Cases in Export Markets

• Product sampling for market evaluation

• Non-clinical investigational studies

• Pre-clinical formulation or toxin comparison projects

• Sales channels requiring low-cost, export-grade neurotoxin

• Institutional procurement in countries with local registration pathways

---

Compliance Statement

This product is manufactured in South Korea and labeled exclusively for overseas export purposes. It is not registered or approved for clinical, cosmetic, or therapeutic use in any domestic market, and must not be used for human or animal injection. All importers, distributors, and end users are responsible for complying with local laws and regulations in their destination country.

---

Tags / Keywords

Hitox, Korean Botulinum Toxin, Export-Grade Toxin, Botulinum Toxin Type A, Botulinum for Export, SNAP-25 Research, Acetylcholine Blockade, Emerging Botulinum Brand, Botulinum Toxin for Distributor Use, GMP Korean Toxin

---

External References

• WHO Fact Sheet on Botulism

• NIH Review on Botulinum Toxin Mechanisms

• PubMed – Botulinum Toxin Type A Research